{"id":60776,"date":"2024-02-28T07:07:41","date_gmt":"2024-02-28T07:07:41","guid":{"rendered":"https:\/\/medsname.com\/tenvir-af\/"},"modified":"2026-05-21T05:27:39","modified_gmt":"2026-05-21T05:27:39","slug":"tenvir-af","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/tenvir-af\/","title":{"rendered":"Tenvir AF"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:16px 20px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin-top:0;\">R\u0103spuns rapid \u2014 Tenvir AF (Tenofovir Alafenamid\u0103 25 mg)<\/h3>\n<ul>\n<li><strong>Substan\u021b\u0103 activ\u0103:<\/strong> tenofovir alafenamid\u0103 fumarat (TAF) 25 mg, comprimat oral, luat o dat\u0103 pe zi cu alimente.<\/li>\n<li><strong>Indica\u021bie principal\u0103 \u00een aceast\u0103 list\u0103:<\/strong> infec\u021bie cronic\u0103 cu virusul hepatitei B (HBV) la adul\u021bi \u2014 suprima\u021bie pe termen lung cu expunere renal\u0103 \u0219i osoas\u0103 semnificativ mai mic\u0103 dec\u00e2t TDF-ul vechi.<\/li>\n<li><strong>Mecanism:<\/strong> inhibitor nucleotidic al transcriptazei inverse (NRTI). Acela\u0219i metabolit activ ca tenofovir disoproxil, dar un prodrog diferit care elibereaz\u0103 tenofovir \u00een hepatocite \u0219i limfocite.<\/li>\n<li><strong>Comparativ cu TDF:<\/strong> ~90% mai pu\u021bin tenofovir \u00een plasm\u0103, ~6\u20137\u00d7 mai mult medicament intracelular. Aceea\u0219i putere antiviral\u0103. Risc mai mic de toxicitate renal\u0103 \u0219i pierdere a densit\u0103\u021bii osoase.<\/li>\n<li><strong>Eficacitate HBV:<\/strong> neinferior fa\u021b\u0103 de TDF pentru suprima\u021bia ADN-ului HBV la 96 de s\u0103pt\u0103m\u00e2ni; markeri de siguran\u021b\u0103 renal\u0103 \u0219i osoas\u0103 semnificativ mai buni \u00een studii comparative.<\/li>\n<li><strong>Avertizare reactivare HBV:<\/strong> exacerbare acut\u0103 sever\u0103 poate ap\u0103rea la \u00eentrerupere. Nu \u00eenceta\u021bi niciodat\u0103 f\u0103r\u0103 supraveghere specializat\u0103.<\/li>\n<\/ul>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Tenvir AF?<\/h2>\n<p>Tenvir AF este un comprimat oral care con\u021bine <strong>tenofovir alafenamid\u0103 fumarat 25 mg<\/strong> (TAF), fabricat de Cipla. Fiecare ambalaj con\u021bine de obicei 30 de comprimate filmate.<\/p>\n<p>TAF este prodrogul de genera\u021bia a doua al tenofovirului, conceput pentru a remedia problemele de toxicitate renal\u0103 \u0219i osoas\u0103 observate la vechiul prodrog TDF (tenofovir disoproxil). Marc\u0103 original\u0103 este <strong>Vemlidy<\/strong> (Gilead, aprobat de FDA pentru hepatita B cronic\u0103 \u00een 2016). Acela\u0219i principiu activ ca TDF, dar cu farmacocinetic\u0103 radical diferit\u0103.<\/p>\n<h2 class=\"wp-block-heading\">Pentru ce se utilizeaz\u0103 Tenvir AF?<\/h2>\n<ul>\n<li><strong>Hepatita B cronic\u0103 (HBC) la adul\u021bi<\/strong> \u2014 antiviral oral de prim\u0103 linie, \u00een special la pacien\u021bii cu boli renale cronice (BRC), osteoporoz\u0103, v\u00e2rst\u0103 &gt; 60 de ani sau toxicitate renal\u0103\/osoas\u0103 preexistent\u0103 legat\u0103 de TDF.<\/li>\n<li><strong>infec\u021bia cu HIV-1<\/strong> \u2014 component al regimurilor combinate (cel mai frecvent asociat cu FTC, dolutegravir sau bictegravir, sau rilpivirina). Nu este utilizat ca monoterapie \u00een HIV.<\/li>\n<li><strong>Profilaxia pre-expunere la HIV (PrEP)<\/strong> \u2014 combina\u021bia TAF + emtricitabin\u0103 (Descovy) este aprobat\u0103 pentru PrEP la b\u0103rba\u021bi cisgender \u0219i femei transgender; TDF\/FTC r\u0103m\u00e2ne preferat pentru persoanele cu risc care ar putea r\u0103m\u00e2ne \u00eens\u0103rcinate.<\/li>\n<\/ul>\n<p>TAF este <strong>prime\u0219te,<\/strong> utilizat \u00een tratamentul hepatitei C, a virusurilor herpetice sau a oric\u0103rei infec\u021bii non-retrovirale \/ non-HBV.<\/p>\n<h2 class=\"wp-block-heading\">De ce TAF \u00een loc de TDF?<\/h2>\n<p>TDF este hidrolizat rapid \u00een plasm\u0103 \u00een tenofovir, expun\u00e2nd rinichii la niveluri ridicate ale medicamentului \u00een circula\u021bie timp de ore. TAF r\u0103m\u00e2ne intact \u00een plasm\u0103 mult mai mult timp, deoarece este un prodrug mai stabil \u0219i este activat preferen\u021bial de esterazele intracelulare din limfocite \u0219i hepatocite (catepsina A, CES1). Rezultatul net:<\/p>\n<table style=\"border-collapse:collapse;width:100%;font-size:14px;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">Marker<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TDF 300 mg<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;text-align:left;\">TAF 25 mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">AUC tenofovir plasmatic<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Ridicat (referin\u021b\u0103)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~90% mai sc\u0103zut<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">TFV-DP intracelular \u00een celule mononucleare sangvine periferice (PBMC)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Referin\u021b\u0103<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">~6\u20137\u00d7 mai ridicat<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Sc\u0103dere eGFR la 96 s\u0103pt. (HBV)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Moderat, dependent de doz\u0103<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Semnificativ mai mic\u0103<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Modificare DMO \u0219old + coloan\u0103 vertebral\u0103<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Reducere mic\u0103<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Reducere mai mic\u0103; uneori recuperare la schimbare<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Efect lipidic<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">U\u0219or favorabil (sc\u0103dere a nivelului de lipide)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">U\u0219or nefavorabil (cre\u0219te LDL\/HDL)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Efectul lipidic este singurul compromis. La pacien\u021bii cu boli cardiovasculare stabilite, TDF poate fi preferat. Pentru majoritatea pacien\u021bilor cu HBV cu factori de risc renali sau oso\u0219i, TAF este op\u021biunea mai sigur\u0103 pe termen lung.<\/p>\n<h2 class=\"wp-block-heading\">Doza \u0219i modul de administrare Tenvir AF<\/h2>\n<ul>\n<li><strong>Hepatit\u0103 B cronic\u0103:<\/strong> un comprimat de 25 mg o dat\u0103 pe zi, \u00een timpul mesei.<\/li>\n<li><strong>HIV (regimuri de combina\u021bie):<\/strong> 25 mg dac\u0103 este combinat cu agen\u021bi ne-potentia\u021bi; 10 mg dac\u0103 este combinat cu un inhibitor CYP3A (cobicistat, ritonavir).<\/li>\n<\/ul>\n<p>Administra\u021bi \u00een timpul mesei \u2014 biodisponibilitatea cre\u0219te cu aproximativ 65% cu o mas\u0103 moderat \u00een gr\u0103simi. \u00cenghi\u021bi\u021bi \u00eentreg. Doze omise: lua\u021bi c\u00e2t mai cur\u00e2nd posibil dac\u0103 v\u0103 aminti\u021bi \u00een decurs de 18 ore; alt\u0103ri s\u0103ri\u021bi \u0219i relua\u021bi urm\u0103torul comprimat programat.<\/p>\n<p><strong>Ajustarea dozei la insuficien\u021b\u0103 renal\u0103:<\/strong> nu este necesar\u0103 ajustare pentru CrCl \u2265 15 mL\/min. Sub 15 mL\/min, utiliza\u021bi doar la pacien\u021bii \u00een hemodializ\u0103 cronic\u0103 (TAF administrat dup\u0103 dializ\u0103 \u00een zilele de dializ\u0103). TAF nu este recomandat \u00een insuficien\u021ba renal\u0103 terminal\u0103 f\u0103r\u0103 dializ\u0103.<\/p>\n<p><strong>Afectare hepatic\u0103:<\/strong> nu este necesar\u0103 ajustare pentru insuficien\u021b\u0103 u\u0219oar\u0103 sau moderat\u0103; nu este recomandat \u00een ciroza decompensat\u0103 (Child-Pugh C).<\/p>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente:<\/strong> cefalee (~10%), dureri abdominale (~5%), oboseal\u0103, tuse, grea\u021b\u0103, dureri lombare. De obicei u\u0219oare \u0219i autolimitante.<\/p>\n<p><strong>Mai pu\u021bin frecvente, dar importante:<\/strong><\/p>\n<ul>\n<li><strong>Modific\u0103ri ale lipidelor<\/strong> \u2014 se a\u0219teapt\u0103 o cre\u0219tere moderat\u0103 a LDL-C, HDL-C, colesterolului total \u0219i a trigliceridelor. Verifica\u021bi din nou lipidele la 3 \u0219i 12 luni. Lua\u021bi \u00een considerare terapia cu statine dac\u0103 riscul cardiovascular este crescut.<\/li>\n<li><strong>Cre\u0219terea \u00een greutate<\/strong> \u2014 studiile privind HIV arat\u0103 o cre\u0219tere de c\u00e2\u021biva kg pe parcursul a 1\u20132 ani la regimurile care con\u021bin TAF fa\u021b\u0103 de TDF (regresia efectului u\u0219or de sc\u0103dere a lipidelor al TDF pare s\u0103 contribuie par\u021bial la aceasta). Mai pu\u021bin stabilit \u00een monoterapia HBV.<\/li>\n<li><strong>Acidoz\u0103 lactic\u0103 cu hepatomegalie sever\u0103<\/strong> \u2014 efect de clas\u0103 rar al NRTI; \u00eentrerupe\u021bi la apari\u021bia unor dureri abdominale progresive neexplicate, respira\u021bie rapid\u0103, oboseal\u0103 sever\u0103.<\/li>\n<li><strong>Exacerbare sever\u0103 a hepatitei B acute la \u00eentrerupere<\/strong> \u2014 acela\u0219i risc de reactivare ca \u0219i TDF. Necesit\u0103 monitorizare timp de cel pu\u021bin 6 luni dup\u0103 \u00eentrerupere.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Inductori puternici ai P-gp<\/strong> \u2014 rifampicin\u0103, rifabutin\u0103, carbamazepin\u0103, fenitoin\u0103, oxcarbazepin\u0103, iarba lui Ioan \u2014 scad expunerea la TAF. Evita\u021bi administrarea concomitent\u0103.<\/li>\n<li><strong>Inhibitori CYP3A<\/strong> \u2014 cobicistat, ritonavir \u2014 cresc semnificativ expunerea la TAF. Utiliza\u021bi forma de 10 mg dac\u0103 este co-administrat\u0103 cu un regim de PI\/INSTI poten\u021biat.<\/li>\n<li><strong>Alte medicamente nefrototoxice<\/strong> \u2014 mai pu\u021bin preocupant dec\u00e2t \u00een cazul TDF, dar este recomandat\u0103 precau\u021bie cu cidofovir, aminoglicozide IV, amfotericina B IV, AINS \u00een doze mari.<\/li>\n<li><strong>Alte produse care con\u021bin tenofovir<\/strong> \u2014 nu combina\u021bi TAF cu TDF, adefovir sau un alt produs care con\u021bine TAF.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cine nu ar trebui s\u0103 ia Tenvir AF?<\/h2>\n<ul>\n<li>Hipersensibilitate cunoscut\u0103 la tenofovir alafenamid\u0103 sau la orice excipient<\/li>\n<li>Insuficien\u021b\u0103 renal\u0103 sever\u0103 (CrCl &lt; 15 mL\/min) care nu este supus\u0103 hemodializei cronice<\/li>\n<li>Ciroz\u0103 decompensat\u0103 (Child-Pugh C)<\/li>\n<li>Administrare concomitent\u0103 cu un inductor puternic al P-gp atunci c\u00e2nd schimbarea nu este posibil\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>Depozita\u021bi sub 30\u00b0C \u00een flaconul original cu desicant. Proteja\u021bi de umiditate. P\u0103stra\u021bi \u00een afara reachii copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">Tenvir AF este acela\u0219i lucru cu Vemlidy?<\/h3>\n<p>Da \u2014 aceea\u0219i molecul\u0103 (tenofovir alafenamid\u0103 25 mg), aceea\u0219i indica\u021bie (hepatit\u0103 B cronic\u0103), aceea\u0219i doz\u0103 o dat\u0103 pe zi. Tenvir AF este versiunea generic\u0103 licen\u021biat\u0103 de Cipla. Vemlidy este produsul original (Gilead).<\/p>\n<h3 class=\"wp-block-heading\">Dac\u0103 TAF este mai bun, de ce mai ia cineva TDF?<\/h3>\n<p>Mai multe motive: TDF are o baz\u0103 de date de siguran\u021b\u0103 de 20 de ani; TDF scade u\u0219or colesterolul LDL (TAF face opusul); datele privind sarcina sunt mai mature pentru TDF; \u0219i TDF este semnificativ mai ieftin. Pentru pacien\u021bii tineri f\u0103r\u0103 probleme renale sau osoase, TDF r\u0103m\u00e2ne o alegere perfect rezonabil\u0103 de prim\u0103 linie. TAF este preferat atunci c\u00e2nd siguran\u021ba renal\u0103 sau osoas\u0103 conteaz\u0103 cel mai mult.<\/p>\n<h3 class=\"wp-block-heading\">Pot s\u0103 trec de la Tenvir (TDF) la Tenvir AF?<\/h3>\n<p>Da, \u0219i mul\u021bi pacien\u021bi fac acest lucru, mai ales dup\u0103 ani de tratament cu TDF c\u00e2nd sc\u0103derile u\u0219oare ale eGFR sau ale densit\u0103\u021bii osoase devin relevante. Trecerea este simpl\u0103: \u00eentrerupe\u021bi TDF \u0219i \u00eencepe\u021bi TAF a doua zi. Suprimarea antiviral\u0103 este men\u021binut\u0103 deoarece ambele forme elibereaz\u0103 acela\u0219i metabolit activ. Markerii renali se \u00eembun\u0103t\u0103\u021besc de obicei \u00een 3\u20136 luni. Verifica\u021bi din nou eGFR, proteinuria \u0219i fosfatemia la 3 luni dup\u0103 schimbare.<\/p>\n<h3 class=\"wp-block-heading\">Va vindeca Tenvir AF hepatita B?<\/h3>\n<p>Niciun antiviral oral nu vindec\u0103 HBV. Tenofovir alafenamida suprim\u0103 replicarea viral\u0103 at\u00e2t de complet \u00eenc\u00e2t ADN-ul viral devine de obicei nedetectabil \u0219i inflama\u021bia hepatic\u0103 se rezolv\u0103 \u2014 dar \u0219ablonul de cccDNA din interiorul hepatocitelor nu este eliminat. Aproximativ 1\u20133% din pacien\u021bi pe an ating vindecarea func\u021bional\u0103 (dispare HBsAg). Pentru majoritatea pacien\u021bilor, tratamentul este pe termen lung.<\/p>\n<h3 class=\"wp-block-heading\">Trebuie s\u0103 m\u0103 a\u0219tept la cre\u0219tere \u00een greutate cu Tenvir AF?<\/h3>\n<p>Datele din terapia combinat\u0103 HIV arat\u0103 o cre\u0219tere modest\u0103 \u00een greutate la regimurile cu TAF fa\u021b\u0103 de TDF, de aproximativ 2\u20134 kg pe parcursul a 96 de s\u0103pt\u0103m\u00e2ni. Efectul este mai mic \u00een monoterapia HBV \u0219i este par\u021bial explicat prin inversarea u\u0219orului dezavantaj metabolic al TDF. Dac\u0103 cre\u0219terea \u00een greutate este \u00eengrijor\u0103toare, monitorizarea lipidelor \u0219i glucozei la baz\u0103 este rezonabil\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua Tenvir AF \u00een timpul sarcinii?<\/h3>\n<p>Datele privind siguran\u021ba TAF \u00een sarcin\u0103 sunt \u00een cre\u0219tere, dar sunt \u00eenc\u0103 mai pu\u021bin mature dec\u00e2t cele pentru TDF. Pentru HBV \u00een sarcin\u0103 avansat\u0103 (s\u0103pt\u0103m\u00e2na 28+) pentru prevenirea transmiterii verticale, TDF este alegerea preferat\u0103 pe baza bazei de date mai extinse de siguran\u021b\u0103. Dac\u0103 sunte\u021bi stabil pe TAF \u0219i r\u0103m\u00e2ne\u021bi \u00eens\u0103rcinat\u0103, discuta\u021bi cu hepatologul \u00eenainte de a schimba \u2014 decizia depinde de \u00eenc\u0103rc\u0103tura viral\u0103, stadiul fibrozei \u0219i trimestrul de sarcin\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Este Tenvir AF activ \u00eempotriva muta\u021biilor de rezisten\u021b\u0103 la HIV?<\/h3>\n<p>TAF \u0219i TDF au acela\u0219i profil de rezisten\u021b\u0103 deoarece elibereaz\u0103 acela\u0219i metabolit activ. Ambele p\u0103streaz\u0103 activitatea \u00eempotriva majorit\u0103\u021bii muta\u021biilor timidin-analog (TAMs), dar eficacitatea este redus\u0103 \u00eempotriva muta\u021biei K65R a transcriptazei inverse. Testarea rezisten\u021bei ar trebui s\u0103 ghideze alegerea regimului atunci c\u00e2nd este disponibil\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Am nevoie de analize de s\u00e2nge \u00eenainte de a \u00eencepe Tenvir AF?<\/h3>\n<p>Da \u2014 HBV DNA de baz\u0103, HBeAg\/anti-HBe, HBsAg, ALT\/AST, hemogram\u0103 complet\u0103, eGFR, analize de urin\u0103 (proteinurie), fosfat seric, panel lipidic \u0219i test HIV anticorp\/antigen. Monitorizarea tratamentului se stabilizeaz\u0103 apoi la fiecare 3\u20136 luni pentru pacien\u021bii stabili.<\/p>\n<h3 class=\"wp-block-heading\">Interac\u021bioneaz\u0103 Tenvir AF cu statinele, medicamentele pentru tensiune sau contraceptia hormonal\u0103?<\/h3>\n<p>Nu exist\u0103 interac\u021biuni clinice semnificative cu statine, inhibitori ACE, ARB, beta-blocante, blocante ale canalelor de calciu sau contraceptia hormonal\u0103. Pu\u021binele interac\u021biuni reale sunt cu inductorii puternici ai P-gp (rifampicin\u0103, anticonvulsivante) \u0219i cu stimulatorii CYP3A (cobicistat, ritonavir).<\/p>\n<h3 class=\"wp-block-heading\">Unde pot comanda Tenvir AF?<\/h3>\n<p>Pute\u021bi comanda Tenvir AF direct de la MedsBase. Furniz\u0103m stocuri originale Cipla cu livrare la nivel mondial. Tratamentul hepatitei cronice B trebuie supravegheat de un hepatolog sau gastroenterolog cu monitorizarea HBV DNA, ALT, eGFR \u0219i HBsAg\/anti-HBs la intervale adecvate.<\/p>\n<h2 class=\"wp-block-heading\">Declinare de responsabilitate<\/h2>\n<p>Informa\u021biile de pe aceast\u0103 pagin\u0103 au scop educa\u021bional \u0219i nu \u00eenlocuiesc sfatul medical profesionist. Tratamentul hepatitei cronice B \u0219i HIV necesit\u0103 evaluare ini\u021bial\u0103, monitorizare specializat\u0103 continu\u0103 \u0219i alegere individualizat\u0103 a regimului. Nu \u00eencepe\u021bi, nu \u00eentrerupe\u021bi \u0219i nu schimba\u021bi terapia pe baz\u0103 de tenofovir f\u0103r\u0103 a consulta un medic calificat.<\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Tenvir-AF (TAF\/FTC) este utilizat pentru PrEP HIV dar nu acoper\u0103 infec\u021biile bacteriene cu transmitere sexual\u0103; dac\u0103 dori\u021bi protec\u021bie \u00een straturi, mul\u021bi utilizatori \u00eel asociaz\u0103 cu doxi-PEP \u2014 oferta noastr\u0103 <a href='\/ro\/prep-starter-pack\/'>Pachetul de pornire PrEP (Tenvir-EM + doxiciclin\u0103 100 mg)<\/a> include regimul stabilit de PrEP TDF\/FTC \u00eempreun\u0103 cu doxiciclin\u0103 pentru preven\u021bia sifilisului, clamidiei \u0219i gonoreei.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Pacien\u021bii care iau <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF<\/a> pentru hepatita B care necesit\u0103 \u0219i profilaxia pre-expunere HIV trebuie s\u0103 \u021bin\u0103 cont c\u0103 <a href=\"https:\/\/medsbase.com\/ro\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarat 300 mg + emtricitabin\u0103 200 mg)<\/a> este regimul de PrEP cu dou\u0103 componente aprobat, combin\u00e2nd TDF cu emtricitabin\u0103 pentru preven\u021bia complet\u0103 a HIV.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Clinicile care \u00ee\u0219i construiesc formularele de TARV \u00een jurul <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF (tenofovir alafenamid\u0103 25 mg)<\/a> ca schelet renal-protector de\u021bin \u0219i <a href=\"https:\/\/medsbase.com\/ro\/avonza\/\">Avonza (TDF \/ lamivudin\u0103 \/ efavirenz)<\/a> pentru pacien\u021bii sensibili la costuri pentru care profilul renal al formul\u0103rii mai vechi cu TDF este acceptabil din punct de vedere clinic.<\/p>\n<p class=\"medsbase-link-boost-2026-05-21\" data-marker=\"mb-link-boost-tavin-em\">Pacien\u021bii care tolereaz\u0103 <a href=\"https:\/\/medsbase.com\/ro\/tenvir-af\/\">Tenvir AF (tenofovir alafenamid\u0103 25 mg)<\/a> dar caut\u0103 o op\u021biune zilnic\u0103 de PrEP mai ieftin\u0103 f\u0103r\u0103 premiumul TAF\/FTC pot lua \u00een considerare <a href=\"https:\/\/medsbase.com\/ro\/tavin-em\/\">Tavin EM (tenofovir disoproxil 300 mg + emtricitabin\u0103 200 mg)<\/a>, scheletul mai vechi de PrEP TDF\/FTC cu cea mai mare baz\u0103 de dovezi.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ebasil\/\">Ebasil<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/budecort-inhaler\/\">Budecort Inhalator<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/fluvoxin\/\">Fluvoxin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/arkamin-h\/\">Arkamin-H<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ivepred\/\">Ivepred<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Trateaz\u0103 infec\u021bia cu HIV<br \/>\n\u2705 Reduce \u00eenc\u0103rc\u0103tura viral\u0103<br \/>\n\u2705 Protejeaz\u0103 rinichii<br \/>\n\u2705 Reduce pierderea osoas\u0103<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te calitatea vie\u021bii<\/p>\n<p><strong>Tenvir AF<\/strong> con\u021bine <strong>Tenofovir<\/strong> <strong>Alafenamid\u0103<\/strong>.<\/p>","protected":false},"featured_media":60777,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334,3304],"product_tag":[3335,4920,4921],"class_list":{"0":"post-60776","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","9":"product_cat-hiv-medication","10":"product_tag-tenofovir","11":"product_tag-tenofovir-alafenamide","12":"product_tag-tenvir-af","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/60776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=60776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/60777"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=60776"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=60776"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=60776"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=60776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}